Lupus Nephritis
Lupus nephritis is an inflammation of the kidneys caused by the autoimmune disease systemic lupus erythematosus (SLE). It is a secondary type of glomerulonephritis that is diagnosed through blood tests, urinalysis, imaging studies, and kidney biopsy.
Health Outcomes
- Achieved Histological Remission
- Activated Immune Response
- Adjusted Immune Function
- Altered CD4+/CD8+ Ratio
- Decreased Peripheral CD3⁺ T Lymphocyte Count
- Delayed Onset of Thrombocytopenia
- Downregulated Complement System Activity
- Elevated Serum TNF-α Levels
- Elevated TNF-α Expression Level
- Enhanced Anti-Inflammatory Cytokine Secretion
- Enhanced Complement Pathway Activity
- Enhanced Immune Regulation
- Enhanced Regulatory T Cell Development
- Enhanced Treg Cell Differentiation
- Improved Alternative Complement Pathway Activity
- Improved Chronic Kidney Disease Outcomes
- Improved Complement C3 Level
- Improved Complement C4 Level
- Improved Connective Tissue Attachment Levels
- Improved Cyclophosphamide-Induced Immunosuppression
- Improved Dendritic Cell Activation
- Improved Estimated Glomerular Filtration Rate
- Improved Granulocyte Oxidative Burst
- Improved Immune Cell Counts
- Improved Immune Homeostasis
- Improved Immune Response in Individuals with Poor Pretreatment
- Improved Immunity Pathways
- Improved Inflammation Levels
- Improved Renal Function
- Improved eGFR
- Increased Anti-Inflammatory Levels
- Increased Anti-inflammatory Cytokines
- Increased Antigen-Specific IgG1 Levels
- Increased C-Reactive Protein Levels
- Increased Complement Component Levels
- Increased Complement Pathway Activity
- Increased Cytokine Production
- Increased Immune Factor Levels
- Increased Immune Marker Activation
- Increased Inflammatory Cytokines
- Increased Lymphocyte Proliferation
- Increased Regulatory T Cell Count
- Increased Relative Weight of Immune Organs
- Increased Systemic Antibody Production
- Increased T-cell Proliferation at 12 Months
- Modulated Immune Cell Activity
- Modulated Immune System
- Modulated Inflammatory Response
- Prevention of Autoimmune Disorders
- Reduced Activated B Cells
- Reduced Aggravation of Chronic Inflammation
- Reduced Anti-dsDNA Positivity
- Reduced B Lymphocyte Proliferation
- Reduced CD25+ Cells
- Reduced Chemokine Levels
- Reduced Complement Component 1q Level
- Reduced Histopathological Damage
- Reduced Immune-Mediated Pathologies
- Reduced Immunoinflammatory Markers
- Reduced Inflammatory Injury
- Reduced Inflammatory Molecules
- Reduced Kidney Function
- Reduced Kidney Injury
- Reduced Lupus-Associated Renal Damage
- Reduced Need for Continuous Renal Replacement Therapy
- Reduced PMN Cell Migration Towards Inflammatory Mediators
- Reduced Plasma Anti-dsDNA Levels
- Reduced Pro-inflammatory Cytokine Production in LPS-stimulated Cells
- Reduced Proinflammatory Cytokines Gene Transcription
- Reduced Proteinuria
- Reduced Renal Inflammation
- Reduced Renal Replacement Therapy
- Reduced Risk of Chronic Inflammatory Diseases
- Reduced Serum TNF-α Levels
- Reduced Steroid Usage
- Reduced Systemic Lupus Erythematosus Disease Activity Index Score
- Reduced Tumor Necrosis Factor Alpha
- Reduced Tumor Necrosis Factor Alpha Production
- Slower CKD Progression
- Stable Kidney Function
- Sustained Immune Function
- Unchanged Spleen Weight Index
- Upregulated Macrophage Inhibitory Factor
- Worsened Autoimmune Manifestations